EMERGENT BIOSOLUTIONS INC. (NYSE:EBS) Files An 8-K Submission of Matters to a Vote of Security Holders

The 2019 annual meeting of stockholders of Emergent BioSolutions Inc. (“Emergent”) was held on May 23, 2019. A total of 47,878,139 shares of Emergent’s common stock were present or represented by proxy, which represented approximately 93.17% of Emergent’s 51,382,454 shares of common stock that were outstanding and entitled to vote at the annual meeting as of the record date of March 28, 2019. Stockholders considered the three proposals outlined below, each of which is described in more detail in the proxy statement.

Proposal 1. To elect three Class I directors to hold office for a term expiring at our 2022 annual meeting of stockholders and one Class II director to hold office for a term expiring at our 2020 annual meeting of stockholders and until their respective successors are duly elected and qualified. All director nominees were elected. The voting results were as follows:

Proposal 2. To ratify the appointment by the Audit Committee of Ernst & Young LLP as our Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2019. Proposal 2 was approved. The voting results were as follows:

Proposal 3. To approve, on an advisory basis, the compensation of our named executive officers. Proposal 3 was approved. The voting results were as follows:

About EMERGENT BIOSOLUTIONS INC. (NYSE:EBS)

Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics in areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Its two operating divisions include Biodefense and Biosciences. The Biodefense division is a pharmaceutical business focused on countermeasures that address public health threats, including chemical, biological, radiological, nuclear and explosives (CBRNE) threats, as well as EID. The Biosciences division is a pharmaceutical business focused on therapeutics in hematology/oncology with secondary on transplantation, infectious disease and autoimmunity.